By Kyle Morris

 

4D pharma PLC said Thursday that a Phase 2 trial of the Blautix drug for irritable bowel syndrome demonstrated structural changes in the gut microbiota of patients.

Blautix could provide a significant solution for millions of patients with IBS, the study's chief investigator said.

4D pharma continues to await feedback from the U.S. Food and Drug Administration regarding the results of its Phase 2 study of Blautix, it said.

Shares in the London-listed pharmaceutical company at 0926 GMT were up 2.9 pence, or 4.8%, at 64 pence.

 

Write to Kyle Morris at kyle.morris@dowjones.com

 

(END) Dow Jones Newswires

December 09, 2021 04:48 ET (09:48 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more 4d Pharma Charts.
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more 4d Pharma Charts.